These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33995819)

  • 1. Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy.
    Eitel T; Zeiner KN; Assmus K; Ackermann H; Zoeller N; Meissner M; Kaufmann R; Kippenberger S; Valesky EM
    World Allergy Organ J; 2021 May; 14(5):100536. PubMed ID: 33995819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.
    Hockenhull J; Elremeli M; Cherry MG; Mahon J; Lai M; Darroch J; Oyee J; Boland A; Dickson R; Dundar Y; Boyle R
    Health Technol Assess; 2012; 16(12):III-IV, 1-110. PubMed ID: 22409877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerated sting challenge in patients on Hymenoptera venom immunotherapy improves health-related quality of life.
    Koschel DS; Schmies M; Weber CN; Höffken G; Balck F
    J Investig Allergol Clin Immunol; 2014; 24(4):226-30. PubMed ID: 25219104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects.
    Adelmeyer J; Pickert J; Pfützner W; Möbs C
    Allergol Select; 2021; 5():57-66. PubMed ID: 33521509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
    Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
    Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Immunotherapy in Hymenoptera Venom Allergy and Concomitant Malignancy: A Retrospective Follow-up Focusing on Effectiveness and Safety.
    Aeberhard J; Haeberli G; Müller UR; Helbling A
    J Investig Allergol Clin Immunol; 2017; 27(6):370-377. PubMed ID: 28675375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of venom immunotherapy on anxiety level of being re-stung].
    Sacha M; Czarnobilska E; Stobiecki M; Dyga W
    Przegl Lek; 2012; 69(12):1261-5. PubMed ID: 23750435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom.
    Oude Elberink JN; De Monchy JG; Van Der Heide S; Guyatt GH; Dubois AE
    J Allergy Clin Immunol; 2002 Jul; 110(1):174-82. PubMed ID: 12110838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in Polish adolescents with Hymenoptera venom allergy treated with venom immunotherapy.
    Cichocka-Jarosz E; Brzyski P; Swiebocka E; Lange J; Tobiasz-Adamczyk B; Lis G; Jedynak-Wąsowicz U; Kulus M; Kaczmarski M; Małaczyńska T; Klajna-Kraluk B; Bręborowicz A; Kycler Z; Pietrzyk JJ
    Arch Med Sci; 2012 Dec; 8(6):1076-82. PubMed ID: 23319984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
    Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Seitz MJ; Aberer W; Bodzenta-Lukaszyk A; Bonifazi F; Campi P; Darsow U; Haeberli G; Hawranek T; Küchenhoff H; Lang R; Quercia O; Reider N; Schmid-Grendelmeier P; Severino M; Sturm GJ; Treudler R; Wüthrich B
    PLoS One; 2013; 8(5):e63233. PubMed ID: 23700415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
    Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
    J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
    Müller U; Helbling A; Berchtold E
    J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological differences between insect venom-allergic patients with and without immunotherapy and asymptomatically sensitized subjects.
    Arzt L; Bokanovic D; Schrautzer C; Laipold K; Möbs C; Pfützner W; Herzog SA; Vollmann J; Reider N; Bohle B; Aberer W; Sturm GJ
    Allergy; 2018 Jun; 73(6):1223-1231. PubMed ID: 29171032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
    Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
    J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical aspects of hymenoptera venom allergy and venom immunotherapy.
    Bilò MB; Tontini C; Martini M; Corsi A; Agolini S; Antonicelli L
    Eur Ann Allergy Clin Immunol; 2019 Nov; 51(6):244-258. PubMed ID: 31594296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venom immunotherapy for preventing allergic reactions to insect stings.
    Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy.
    Severino M; Simioni L; Bonadonna P; Cantone R; Cortellini G; Crescioli S; D'Angelo A; La Rosa L; Macchia D; Martignago I; Massolo A; Reccardini F; Bagnasco D; Passalacqua G
    World Allergy Organ J; 2019 Dec; 12(12):100086. PubMed ID: 31768218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors in Hymenoptera venom allergy.
    Ruëff F; Kroth J; Przybilla B
    Allergol Select; 2017; 1(1):53-58. PubMed ID: 30402602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice.
    Bonifazi F; Jutel M; Biló BM; Birnbaum J; Muller U;
    Allergy; 2005 Dec; 60(12):1459-70. PubMed ID: 16266376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.